SPARK Microgravity GmbH

SPARK Microgravity GmbH website preview
growth biotech Berlin 4 sources
Own this company? Claim the page to unlock editing and verified-owner badge.

SPARK Microgravity operates the world's first orbital space laboratory for pharmaceutical R&D, providing end-to-end mission services for drug discovery and biotechnology research in microgravity.

Classification

Berlin DE growth biotech services b2b bioinformatics Health

Profile

Founded
2011
Headcount
20-50
Tech stack
spaceflight hardware, mission control software, scientific instrumentation
Revenue range
unknown

Funding

Funding details not yet available.

Business model
💡 Value Proposition

Enables pharmaceutical R&D and biotechnology research in microgravity through the world’s first orbital space laboratory.

👥 Customer Segments

Pharmaceutical companies and biotechnology firms seeking drug discovery and rapid hypothesis testing capabilities.

💰 Revenue Model

End-to-end mission services including experiment design, payload integration, launch coordination, and on-orbit support.

📡 Channels

Direct engagement with specialized industry leaders and presence at high-level space technology forums.

🤝 Key Partnerships

Commercial space stations with standardized docking (IDSS) and visiting vehicles like Dream Chaser for return logistics.

⚖️ Cost Structure

Complex logistics involving payload integration, launch coordination, and on-orbit mission support operations.

🏗️ Key Resources

The world’s first orbital space laboratory for pharmaceutical R&D and proprietary end-to-end mission service infrastructure.

⚙️ Key Activities

Orbital pharmaceutical lab operations, experiment design, payload integration, launch coordination, and on-orbit support.

💬 Customer Relationships

Sales-led service model for high-value, specialized clients requiring complex scientific mission execution.

Strategic analysis
🏁 Competitive landscape

Unique position as the first orbital pharma lab; competes with commercial space stations enabling rapid 30-60 day research cycles.

🎯 Market pains

Need for controlled downmass, rapid hypothesis testing, and compressed iteration cycles in biotechnology drug discovery.

💎 Improvement suggestions
  • Scale Subscription Revenue: Introduce tiered analytics subscriptions (basic, advanced, enterprise) to smooth cash flow and reduce relianc
♟️ Strategic implications
  • Map Customer Journey: Build a detailed funnel (awareness → inquiry → mission design → data delivery) and assign KPI owners for conversion
🛡️ Credibility notes
  • Strong Institutional Backing: Partnership with NASA Ames and recent EU Deep-Tech Champion award (2025) demonstrate technical credibility
Team

Team details not yet available.

Investors

No investors recorded yet.

Sources & references

Web verified · 4 sources
Enriched 18 Jun 2026